Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Sponsor: Pfizer
Summary
A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.
Official title: HYMPAVZI S.C. INJECTION 150 mg Pen SPECIAL INVESTIGATION
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-10-30
Completion Date
2030-04-11
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
Marstacimab
For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.
Locations (1)
Pfizer
Tokyo, Japan